Skip to content

Study · In vitro (cells) · sheep · 1994

10 results

The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist.

Wu D, Chen C, Katoh K, Zhang J, Clarke IJ

The Journal of endocrinology1 Feb 1994Cited by 34 (Europe PMC)

PMID8169551 (opens in a new tab)DOI10.1677/joe.0.140r009 (opens in a new tab)PepBankPUB-08169551
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, KP 102 (GHRP‑2) caused a dose-dependent increase in GH secretion.

    In plain wordsIn lab-grown sheep pituitary cells, GHRP‑2 caused a dose-dependent rise in growth hormone release.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion after KP 102
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Application of KP 102 to the perifusion medium caused a dose-dependent increase in GH secretion.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.
  2. 02LabIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, KP 102 had similar potency to GRF.

    In plain wordsIn lab-grown sheep pituitary cells, GHRP‑2 was about as potent as GRF at releasing growth hormone.

    Peptide
    GHRP-2
    Outcome
    No significant changePotency of KP 102 versus GRF
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    GRF
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dose-response relationships indicated that KP 102 had similar potency to GRF
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.
  3. 03LabIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, KP 102 was 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1).

    In plain wordsIn lab-grown sheep pituitary cells, GHRP‑2 was 10-fold more potent than older GHRP-6 and GHRP-1 for growth hormone release.

    Peptide
    GHRP-2
    Outcome
    IncreasePotency of KP 102 versus GHRP-6 and GHRP-1
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    GHRP-6 and GHRP-1
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and was 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1) tested in same system.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.
  4. 04LabIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, earlier generations of GH-releasing peptide (GHRP‑6 and GHRP-1) were about 10-fold less potent than KP 102.

    In plain wordsIn lab-grown sheep pituitary cells, older GHRP‑6 and GHRP-1 were about 10-fold less potent than GHRP-2 at releasing growth hormone.

    Peptide
    GHRP-6
    Outcome
    DecreasePotency of GHRP-6 and GHRP-1 versus KP 102
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    KP 102 (GHRP-2)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and was 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1) tested in same system.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.
  5. 05LabIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, the GH response to a second application of KP 102 within 1 h was significantly lower than the first.

    In plain wordsIn lab-grown sheep pituitary cells, a second GHRP‑2 dose within 1 hour produced a smaller growth hormone response than the first.

    Peptide
    GHRP-2
    Outcome
    DecreaseRepeat KP 102 application within 1 h
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    First application
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The response to a second application of KP 102 given within 1 h of initial application was significantly lower than the response to the first application.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

Studies that did not test the peptide alone5

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 06LabNot a test of GHRP-2 aloneIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, when KP 102 or GRF was applied first and the other 1 h later, the second response was not attenuated.

    In plain wordsIn lab-grown sheep pituitary cells, giving GHRP‑2 and then GRF an hour later (or the reverse) did not weaken the second response.

    Peptide
    GHRP-2
    Outcome
    No significant changeSequential KP 102 and GRF applications
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    When KP 102 (or GRF) was applied first and then GRF (or KP 102) given 1 h later, the second response was not attenuated.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 07LabNot a test of GHRP-2 aloneIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, coadministration of GRF and KP 102 gave an additive effect on GH release.

    In plain wordsIn lab-grown sheep pituitary cells, GRF and GHRP‑2 together released growth hormone in an additive way.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH release with KP 102 and GRF coadministered
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    When GRF and KP 102 were coadministered, an additive effect on release of GH was obtained.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 08LabNot a test of GHRP-2 aloneIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, the GH release caused by a maximal dose of KP 102 (100 nM) was totally abolished by a GRF receptor antagonist.

    In plain wordsIn lab-grown sheep pituitary cells, a GRF receptor blocker completely stopped the growth hormone release caused by GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    DecreaseKP 102 GH release after GRF receptor antagonist
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    GRF receptor antagonist [Ac-Tyr1,D-Arg2] GRF 1-29 (1 microM)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The effect of maximal dose of KP 102 (100 nM) on GH release was totally abolished by [Ac-Tyr1,D-Arg2] GRF 1-29 (1 microM) which is believed to be a specific antagonist for the GRF receptor.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 09LabNot a test of GHRP-2 aloneIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, blockade of Ca2+ channels by Cd2+ abolished the increase in GH release in response to KP 102 (100 nM).

    In plain wordsIn lab-grown sheep pituitary cells, blocking calcium channels stopped GHRP‑2 from raising growth hormone release.

    Peptide
    GHRP-2
    Outcome
    DecreaseKP 102 GH release after Ca2+ channel blockade
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Comparator
    Cd2+ 2 mM
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Blockade of Ca2+ channels by Cd2+ (2 mM) diminished the basal GH secretion and abolished the increase in GH release in response to KP 102 (100 nM).
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 10LabNot a test of GHRP-2 aloneIn vitro (cells)Efficacy outcome

    In perifused ovine pituitary cells, there was no cross-desensitization between KP 102 and GRF responses.

    In plain wordsIn lab-grown sheep pituitary cells, responses to GHRP‑2 and GRF did not weaken each other.

    Peptide
    GHRP-2
    Outcome
    No significant changeCross-desensitization between KP 102 and GRF
    Study

    sheepn: not reported in source

    Primary cultured ovine anterior pituitary cells (perifusion)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    there is no cross-desensitization between KP 102 and GRF responses.
    1 context sentence
    Summary · context
    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.